Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal.
The stock’s move wasn’t a mystery rally.
The surge was a classic takeover repricing: once Gilead and Arcellx signed a definitive deal at $115 a share, traders quickly bid ACLX up toward that buyout price.
The deal math: $115 cash, plus a $5 “if-it-happens” kicker
Gilead said it will pay $115 per Arcellx share in cash at closing, plus one non-transferable contingent value right (CVR) worth an additional $5 per share if a sales target is met.
A CVR is essentially an IOU tied to a future milestone: shareholders receive additional compensation only if the acquired drug performs well enough after launch.
In this case, the CVR pays out if Arcellx’s lead therapy, anito-cel, reaches at least $6 billion in cumulative global net sales from launch through the end of 2029.
The $115 cash price plus the CVR represented a premium of about 87% to Arcellx’s previous close, which explains why the stock surged toward the takeout price almost immediately.
The transaction is structured as a tender offer followed by a second-step merger at the same consideration, and it has already been approved by both companies’ boards.
Gilead also disclosed it already owns about 11.5% of Arcellx’s outstanding shares.
Gilead’s stock, meanwhile, was modestly lower in premarket trade, about a 1% dip, an often-seen reaction when a large-cap buyer commits billions in cash.
Gilead said the acquisition is expected to be accretive to earnings per share starting in 2028 and beyond, assuming FDA approval for the drug.
Also Read: Novo stock drops 15% as obesity drug falls short in key trial
Arcellx stock: The strategic prize
Gilead is paying up for a very specific asset: anitocabtagene autoleucel, known as anito-cel, an investigational BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma.
CAR-T, short for chimeric antigen receptor T-cell therapy, is a form of personalized cancer treatment where a patient’s own immune cells are engineered to better recognize and attack cancer.
The commercial opportunity is large, but so is the competition.
The multiple myeloma CAR-T category is currently led by Johnson & Johnson and Legend Biotech’s Carvykti, a benchmark that rivals are trying to match on efficacy, safety, and the ability to manufacture at scale.
Arcellx has previously released data that analysts viewed as supportive of anito-cel’s potential in this market, with Fierce Biotech noting comparisons being drawn against Carvykti as datasets have matured.
The timeline is also a key driver of deal urgency.
The FDA is evaluating anito-cel with a decision expected by Dec. 23, 2026, which keeps the story in an active, near-launch window rather than a distant research bet.
Gilead also pointed to the partnership history here as the companies have been collaborators in cell therapy since 2022, and this buyout consolidates control of a program Gilead already knows well.
The post Why is Arcellx stock up 80% today? Gilead’s $7.8B answer appeared first on Invezz
